Albireo Pharma (ALBO) Reports Q3 Loss of $1.17, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Albireo Reports Third Quarter 2018 Financial Results
November 13, 2018 7:00 AM ESTOdevixibat selected as International Nonproprietary Name (INN) for A4250
A4250 granted Fast Track and additional Orphan Drug designations
A4250 Phase 3 trial progressing as planned, new natural history data presented at AASLD
Management to host conference call and webcast today at 8:30 a.m. EST
BOSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced financial results and corporate highlights for the third quarter ended September... More
